IC
Ikarian Capital Portfolio holdings
AUM
$302M
1-Year Return
65.21%
This Quarter Return
+7.96%
1 Year Return
+65.21%
3 Year Return
+441.33%
5 Year Return
+548.26%
10 Year Return
–
AUM
$322M
AUM Growth
+$1.54M
(+0.48%)
Cap. Flow
-$8.3M
Cap. Flow
% of AUM
-2.58%
Top 10 Holdings %
Top 10 Hldgs %
44.05%
Holding
134
New
20
Increased
8
Reduced
29
Closed
9
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$11.4M |
| 2 |
Ultragenyx Pharmaceutical
RARE
|
$9.94M |
| 3 |
Arcus Biosciences
RCUS
|
$9.16M |
| 4 |
Spyre Therapeutics
SYRE
|
$8.89M |
| 5 |
Avalo Therapeutics
AVTX
|
$8.7M |
Top Sells
| 1 |
Sarepta Therapeutics
SRPT
|
$18.7M |
| 2 |
Soleno Therapeutics
SLNO
|
$11.3M |
| 3 |
Nuvalent
NUVL
|
$10.2M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$8.27M |
| 5 |
Amgen
AMGN
|
$8.06M |
Sector Composition
| 1 | Healthcare | 99.61% |
| 2 | Real Estate | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Amgen
AMGN
$152B
| $4.29M | 0.6% |
13,300
-25,000
| -65% | -$8.06M |
|
27
Xenon Pharmaceuticals
XENE
$3.03B
| $4.22M | 0.59% |
107,187
| – | – |
|
28
Evolus
EOLS
$499M
| $4.18M | 0.58% |
+258,279
| New | +$4.18M |
|
29
Abeona Therapeutics
ABEO
$356M
| $3.69M | 0.51% |
583,593
-185,000
| -24% | -$1.17M |
|
30
Rocket Pharmaceuticals
RCKT
$353M
| $3.64M | 0.51% |
197,096
| – | – |
|
31
Pyxis Oncology
PYXS
$100M
| $3.51M | 0.49% |
957,408
-705,000
| -42% | -$2.59M |
|
|
SLN
32
Silence Therapeutics
SLN
$257M
| $3.37M | 0.47% |
587,343
+80,678
| +16% | +$463K |
|
|
SLRN
33
DELISTED
ACELYRIN
SLRN
| $3.34M | 0.47% |
677,074
-798,000
| -54% | -$3.93M |
|
|
CYBN
34
Cybin
CYBN
$144M
| $3.26M | 0.46% |
367,195
-2
| -0% | -$18 |
|
35
CervoMed
CRVO
$87.2M
| $2.95M | 0.41% |
202,345
-35,000
| -15% | -$511K |
|
36
Tourmaline Bio
TRML
$689M
| $2.79M | 0.39% |
108,483
| – | – |
|
37
Terns Pharmaceuticals
TERN
$630M
| $2.57M | 0.36% |
308,497
-150,000
| -33% | -$1.25M |
|
38
Alnylam Pharmaceuticals
ALNY
$59.2B
| $2.4M | 0.34% |
+8,741
| New | +$2.4M |
|
39
Lexeo Therapeutics
LXEO
$279M
| $2.33M | 0.32% |
+257,216
| New | +$2.33M |
|
40
Mineralys Therapeutics
MLYS
$2.22B
| $2.18M | 0.3% |
+180,000
| New | +$2.18M |
|
|
OKUR
41
OnKure Therapeutics, Inc. Class A Common Stock
OKUR
$36.1M
| $1.74M | 0.24% |
+102,567
| New | +$1.74M |
|
42
Nektar Therapeutics
NKTR
$716M
| $1.71M | 0.24% |
87,494
| – | – |
|
43
Monte Rosa Therapeutics
GLUE
$306M
| $1.65M | 0.23% |
+311,593
| New | +$1.65M |
|
|
ONC
44
BeOne Medicines Ltd. American Depositary Shares
ONC
$37.2B
| $1.64M | 0.23% |
+88,167
| New | +$1.64M |
|
|
ACHL
45
DELISTED
Achilles Therapeutics plc American Depositary Shares
ACHL
| $1.47M | 0.21% |
1,443,181
| – | – |
|
46
iBio
IBIO
$15.9M
| $1.33M | 0.19% |
600,000
| – | – |
|
|
CMPS
47
Compass Pathways
CMPS
$479M
| $1.28M | 0.18% |
202,908
-100,000
| -33% | -$630K |
|
48
Kodiak Sciences
KOD
$457M
| $1.24M | 0.17% |
476,586
| – | – |
|
|
MRNS
49
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $1.24M | 0.17% |
706,154
| – | – |
|
50
Roivant Sciences
ROIV
$8.82B
| $1.16M | 0.16% |
100,609
| – | – |
|